迭代卫生经济学评价在晚期非小细胞肺癌全基因组测序成本效益中的应用更新
An Application of Iterative Health Economic Evaluation: An Update on the Early Cost Effectiveness of Whole-Genome Sequencing in Advanced Non-small-Cell Lung Cancer
作者：Andrea Fernández Coves、Bram Ramaekers、Martijn Simons、Lucas F. van Schaik、Sabine Grimm、Valesca P. Retèl、Manuela Joore
单位：Department of Clinical Epidemiology & Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, Maastricht, the Netherlands; Department of Clinical Epidemiology and Medical Technology Assessment, Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Centre+, Maastricht, The Netherlands. Electronic address: andrea.fernandez.coves@mumc.nl.；Department of Clinical Epidemiology & Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, Maastricht, the Netherlands; Department of Clinical Epidemiology and Medical Technology Assessment, Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Centre+, Maastricht, The Netherlands.；Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, P.O. Box 90203, 1006 BE, Amsterdam, The Netherlands.
摘要
该研究发表在《Value in Health》期刊，针对晚期非小细胞肺癌患者采用全基因组测序（WGS）进行成本效益分析的迭代更新。研究结果可为基因检测技术在肿瘤精准诊疗中的卫生技术评估（HTA）及医保准入决策提供参考。
AI 主编 · 推荐理由推荐理由
涉及基因检测产品的卫生经济学证据，对IVD企业的市场准入策略和医保谈判准备有参考价值，建议企业关注WGS在肺癌领域的真实世界应用数据积累。